Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | ARG2 | P78540 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TOP1 | P11387 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL107005 | 1.00 | MAOB (0.61) | MAOBCA1CA2ARG2TAAR1 | |
| SCHEMBL23096926 | 0.83 | MAOB (0.56) | MAOBCA1CA2ARG2TAAR1 | |
| SCHEMBL109777 | 0.81 | MAOB (0.54) | MAOBCA1CA2ARG2TAAR1 | |
| SCHEMBL448031 | 0.81 | MAOB (0.54) | MAOBCA1CA2ARG2TAAR1 | |
| SCHEMBL10348037 | 0.81 | MAOB (0.54) | MAOBCA1CA2ARG2TAAR1 | |
| SCHEMBL16295813 | 0.78 | MAOB (0.34) | MAOB | |
| SCHEMBL106720 | 0.78 | GPR52 (0.47) | — | |
| SCHEMBL107344 | 0.78 | TAAR1 (0.45) | TAAR1SLC6A2 | |
| SCHEMBL451147 | 0.78 | GPR52 (0.47) | — | |
| SCHEMBL107343 | 0.78 | TAAR1 (0.45) | TAAR1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090155873-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-06-18 | — | — | US | claimed |
| US-20090139134-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-06-04 | — | — | US | claimed |
| WO-2009046370-A2 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-04-09 | — | — | WO | claimed |
| EP-1021424-B1 | THIADIAZOLE AMIDE MMP INHIBITORS | UPJOHN CO (US) | 2003-02-26 | — | — | EP | claimed |
| EP-1021424-A1 | THIADIAZOLE AMIDE MMP INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-26 | — | — | EP | claimed |
| US-5830869-A | METALLOPROTEASE INHIBITOR | PHARMACIA & UPJOHN COMPANY | 1998-11-03 | — | — | US | claimed |
| WO-1997048688-A1 | THIADIAZOLE AMIDE MMP INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1997-12-24 | — | — | WO | claimed |
| EP-3230463-B2 | RAPID PRETREATMENT | APALTA PATENTS OUE (EE) | 2025-07-16 | — | — | EP | disclosed |
| US-20240425893-A1 | RAPID PRETREATMENT | Apalta Patents OÜ (EE) | 2024-12-26 | — | — | US | disclosed |
| US-12054761-B2 | Rapid pretreatment | Apalta Patents OÜ (EE) | 2024-08-06 | — | — | US | disclosed |
| US-11821047-B2 | High pressure zone formation for pretreatment | Apalta Patent OÜ (EE) | 2023-11-21 | — | — | US | disclosed |
| US-20230295678-A1 | RAPID PRETREATMENT | Apalta Patents OÜ (EE) | 2023-09-21 | — | — | US | disclosed |
| EP-4098750-A1 | RAPID PRETREATMENT | Sweetwater Energy, Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| WO-2009046375-A2 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| EP-1021424-B1 | THIADIAZOLE AMIDE MMP INHIBITORS | UPJOHN CO (US) | 2003-02-26 | — | — | EP | disclosed |
| EP-1021424-A1 | THIADIAZOLE AMIDE MMP INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-26 | — | — | EP | disclosed |
| US-5830869-A | METALLOPROTEASE INHIBITOR | PHARMACIA & UPJOHN COMPANY | 1998-11-03 | — | — | US | disclosed |
| WO-1997048688-A1 | THIADIAZOLE AMIDE MMP INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1997-12-24 | — | — | WO | disclosed |
| US-4230894-A | ISOMER SEPARATION BY CATALYTIC CRACKING USING A SELECTIVE ZEOLITE | MOBIL OIL CORPORATION (US) | 1980-10-28 | — | — | US | disclosed |
| US-4205189-A | Method for producing 3-alkylphenols and 1,3-dihydroxybenzene | MOBIL OIL CORPORATION (US) | 1980-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090139134-A1 | BIOFUEL PRODUCTION | MGAM, DCXR, MANBA | MAOB 862/4885CA1 2232/4885CA2 3146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.